Virus cocktail targets stubborn lung infection in cystic fibrosis patients
NCT ID NCT07275905
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-stage trial tests whether a mixture of natural viruses, called AchromoPhage, is safe for adults with cystic fibrosis who have long-term lung infections from Achromobacter bacteria. Twelve participants will receive the treatment by inhalation, IV, or both, and be monitored for side effects and changes in lung function. The goal is to find a new way to control these hard-to-treat infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California San Diego (UCSD)
San Diego, California, 92037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.